Briefing
Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.
People with stage IV melanoma treated with anti-PD-1 therapy had serial tumor-informed ctDNA testing, and a landmark analysis at 6 and 9 months was used to assess progression. The abstract does not name the manufacturer.
- Design: Evidence level 3
- Assay: Not named in the abstract